Anja Rohenkohl1, Susanne Stalman2, Gerdine Kamp3, Monika Bullinger4, Julia Quitmann5. 1. Department of Medical Psychology, University Medical Center Hamburg - Eppendorf, Martinistr. 52, Building W26, 20246, Hamburg, Germany. a.rohenkohl@uke.de. 2. Department of Pediatrics, Tergooi Hospital, Blaricum, The Netherlands. se.stalman@gmail.com. 3. Department of Pediatrics, Tergooi Hospital, Blaricum, The Netherlands. gkamp@tergooi.nl. 4. Department of Medical Psychology, University Medical Center Hamburg - Eppendorf, Martinistr. 52, Building W26, 20246, Hamburg, Germany. bullinger@uke.de. 5. Department of Medical Psychology, University Medical Center Hamburg - Eppendorf, Martinistr. 52, Building W26, 20246, Hamburg, Germany. j.quitmann@uke.de.
Abstract
UNLABELLED: The European Quality of Life in Short Stature Youth (QoLISSY) questionnaire is a disease-specific instrument assessing quality of life (QoL) in children with short stature from the child and parent perspectives. In order to use the QoLISSY in Dutch samples, a translation process and psychometric testing is needed. Children diagnosed with short stature (8 to 18 years) and their parents were recruited from a Dutch growth clinic. Reliability was assessed using Cronbach's α and intraclass correlation coefficients (ICCs). Pearsons' correlations with the generic KIDSCREEN and a confirmatory factor analysis (CFA) were performed to test validity. Scales showed good internal consistency with α ranging from 0.80 to 0.94 (child report) and from 0.85 to 0.95 (parent report). Test-retest reliability (ICC) ranged from 0.15 to 0.91 (child report) and from 0.14 to 0.83 (parent report). Correlations with the KIDSCREEN in the mean range indicated criterion validity. The models' goodness of fit was confirmed by CFA results in the Dutch and in comparison with the European sample. CONCLUSION: The Dutch QoLISSY is a psychometrically reliable and valid short stature-specific QoL measure. It is now available for use in clinical research and practice to evaluate well-being and possible effects of growth hormone treatment and psychological interventions in the Netherlands.
UNLABELLED: The European Quality of Life in Short Stature Youth (QoLISSY) questionnaire is a disease-specific instrument assessing quality of life (QoL) in children with short stature from the child and parent perspectives. In order to use the QoLISSY in Dutch samples, a translation process and psychometric testing is needed. Children diagnosed with short stature (8 to 18 years) and their parents were recruited from a Dutch growth clinic. Reliability was assessed using Cronbach's α and intraclass correlation coefficients (ICCs). Pearsons' correlations with the generic KIDSCREEN and a confirmatory factor analysis (CFA) were performed to test validity. Scales showed good internal consistency with α ranging from 0.80 to 0.94 (child report) and from 0.85 to 0.95 (parent report). Test-retest reliability (ICC) ranged from 0.15 to 0.91 (child report) and from 0.14 to 0.83 (parent report). Correlations with the KIDSCREEN in the mean range indicated criterion validity. The models' goodness of fit was confirmed by CFA results in the Dutch and in comparison with the European sample. CONCLUSION: The Dutch QoLISSY is a psychometrically reliable and valid short stature-specific QoL measure. It is now available for use in clinical research and practice to evaluate well-being and possible effects of growth hormone treatment and psychological interventions in the Netherlands.
Entities:
Keywords:
Children; Growth hormone (treatment); Psychometric testing; Quality of life; Short stature
Authors: Toshiaki Tanaka; Pinchas Cohen; Peter E Clayton; Zvi Laron; Raymond L Hintz; Pierre C Sizonenko Journal: Growth Horm IGF Res Date: 2002-10 Impact factor: 2.372
Authors: Yvonne Schönbeck; Henk Talma; Paula van Dommelen; Boudewijn Bakker; Simone E Buitendijk; Remy A HiraSing; Stef van Buuren Journal: Pediatr Res Date: 2012-12-10 Impact factor: 3.756
Authors: Julia Quitmann; Anja Rohenkohl; Monika Bullinger; John E Chaplin; Michael Herdman; Dolores Sanz; Emmanuelle Mimoun; Eva Feigerlova; Kendra DeBusk; Michael Power; Hartmut Wollmann; Andreas Pleil Journal: Pediatr Endocrinol Rev Date: 2013-12
Authors: P Cohen; A D Rogol; C L Deal; P Saenger; E O Reiter; J L Ross; S D Chernausek; M O Savage; J M Wit Journal: J Clin Endocrinol Metab Date: 2008-09-09 Impact factor: 5.958
Authors: Linde Scholten; Agnes M Willemen; Bob F Last; Heleen Maurice-Stam; Elisabeth M van Dijk; Elske Ensink; Noortje Zandbelt; Aafke van der Hoop-Mooij; Carlo Schuengel; Martha A Grootenhuis Journal: Pediatrics Date: 2013-03-11 Impact factor: 7.124
Authors: Kerstin Albertsson-Wikland; A Stefan Aronson; Jan Gustafsson; Lars Hagenäs; Sten A Ivarsson; Björn Jonsson; Berit Kriström; Claude Marcus; Karl Olof Nilsson; E Martin Ritzén; Torsten Tuvemo; Otto Westphal; Jan Aman Journal: J Clin Endocrinol Metab Date: 2008-08-26 Impact factor: 5.958
Authors: Sara Casaña-Granell; Laura Lacomba-Trejo; Inmaculada Montoya-Castilla; Marián Pérez-Marín Journal: Qual Life Res Date: 2021-03-04 Impact factor: 4.147
Authors: J Quitmann; A Giammarco; M Maghnie; F Napoli; I Di Giovanni; C Carducci; A Mohn; M Bullinger; R Sommer Journal: J Endocrinol Invest Date: 2017-04-10 Impact factor: 4.256